(RTTNews) - The Malaysia stock market has moved higher in two straight sessions, gathering almost a dozen points or 0.7 percent along the way. The Kuala Composite Index now rests just beneath the 1,610-point plateau and it figures to tick higher again on Monday.
The global forecast for the Asian market is cautiously optimistic, with upside limited by surging coronavirus cases in India. The European markets were down and the U.S. bourses were up and the Asian markets figure to split the difference.
The KLCI finished barely higher on Friday as gains from the glove makers were offset by weakness from the financial shares and plantation stocks.
For the day, the index rose 0.70 points or 0.04 percent to finish at 1,608.43 after trading between 1,605.44 and 1,610.81. Volume was 6.549 billion shares worth 4.189 billion ringgit. There were 574 gainers and 478 decliners.
Among the actives, Axiata jumped 1.06 percent, while CIMB Group plummeted 1.18 percent, Dialog Group climbed 0.97 percent, Digi.com tanked 0.95 percent, Genting gained 0.20 percent, Hartalega Holdings soared 2.28 percent, IHH Healthcare lost 0.36 percent, Kuala Lumpur Kepong fell 0.28 percent, Maybank slid 0.24 percent, Maxis dropped 0.43 percent, MISC eased 0.15 percent, Petronas Chemicals skidded 0.51 percent, PPB Group rose 0.11 percent, Press Metal rallied 1.73 percent, Public Bank tumbled 0.71 percent, RHB Capital plunged 1.13 percent, Sime Darby advanced 0.44 percent, Sime Darby Plantations sank 0.45 percent, Supermax surged 3.12 percent, Telekom Malaysia added 0.35 percent, Tenaga Nasional shed 0.40 percent, Top Glove spiked 1.96 percent and Genting Malaysia and IOI Corporation were unchanged.
The lead from Wall Street is positive as the major averages showed a strong move to the upside, picking up steam as the session progressed.
The Dow spiked 227.59 points or 0.67 percent, while the NASDAQ jumped 198.39 points or 1.44 percent to end at 14,016.81 and the S&P 500 gained 45.19 points or 1.09 percent to close at 4,180.17. For the week, the Dow fell 0.5 percent, the NASDAQ shed 1.4 percent and the S&P eased 0.1 percent.
The rebound on Wall Street partly reflected the volatility seen over the past few sessions, which saw the major averages show big swings back-and-forth.
Optimism about the economic recovery has helped prop up the markets, although concerns about high valuations and surging coronavirus cases overseas have led to worries about the near-term outlook.
In economic news, the Commerce Department reported a substantial rebound in new home sales in March, sending sales to their highest level since August 2006.
Crude oil prices moved higher on Friday, lifted by buoyant demand for energy in the U.S. despite a weak global outlook. West Texas Intermediate Crude futures for June ended up by $0.71 or 1.2 percent at $62.14 a barrel. WTI crude futures shed 1.7 percent in the week.
You can now follow your favourite workout routine, get to deep work with LoFi music, or do a quick meditation session from the comfort of your Mac BENGALURU, India, May 1, 2021 /PRNewswire/ -- Global health and fitness platform Ultrahuman officially launched its Mac app to help users meditate, get to deep work with LoFi music & productivity playlists, & even workout from the comfort of their Mac.With the launch of the beautifully designed Mac app, accessing content from the world's best fitness experts has become even more seamless and simple."Office workers spend a jaw-dropping 1,700 hours a year in front of a computer - and that's just in the US. With Ultrahuman Mac app launch, our users' favourite work screen is now their favourite workout, mindfulness and sleep destination as well! Within a few days of launch, we were trending on #1 on Mac Store which also shows that people need seamless and quick access to their favourite relaxation, productivity and fitness apps, especially as we embrace the Work From Home culture," said Mohit Kumar, Founder & CEO, Ultrahuman.More about Ultrahuman
Ultrahuman is a fitness platform that helps people meditate, workout efficiently, and optimize their sleep with the help of athletes, neuroscientists, artists, and psychologists—all in one place. It was officially launched at the world's largest tech exhibition, CES, in January 2021.The core differentiator of the Ultrahuman app is bringing the best athletes, fitness coaches and psychologists in the world on one platform. Partners include leading athletes and celebrities like Crossfit world champion Kara Saunders, fitness celebrity Amanda Cerny, coach Johannes Bartl, hybrid athlete, and coach Kris Gethin, MindSize CEO Christian Straka, UCLA Mindfulness Director Diana Winston, to name a few.Biofeedback TechnologyCompared to Calm and Headspace's celebrity content approach—Ultrahuman uses a technology platform-based approach to improve the experience and sustainable long-term results.The Ultrahuman app integrates with the Apple Watch to provide real-time biofeedback to measure and improve the efficacy of meditation and workouts. You can not only see the calories burned and your heart rate but also track your progress day-on-day. Also, for the first time, you can see the impact of your meditation session with a drop in your heart rate as you feel less stressed and more relaxed.
Ever-growing fitness content library from top global expertsUltrahuman features an ever-growing library of thousands of hours of content across Body Workouts, Meditation, Bedtime Stories, and Brain Music categories designed by experts to empower users to unleash their personal best in mind and body.● Workouts: There are body Body Workout programs - including HIIT classes, Yoga, running, and more designed for all fitness levels. What makes each program unique is the combination of mind, body, and recovery that empowers users to maximize results and stay focused on consistent practice.● Meditation: The life-changing skill of meditation backed by cutting-edge research is the core of the experience.● Bedtime Stories: Bedtime Stories written by award-winning authors are designed to educate, delight, and relax users into sleep.
● Brain Music: Music from various neuro-musicians, classical music legends, and artists, including Grammy Award winners, is designed to relax, help with focus and productivity, sleep, and more.Assets are available for download here. Press Contact - email@example.comAbout Ultrahuman: Ultrahuman is a fitness platform that helps people meditate, workout efficiently, and optimize their sleep with the help of athletes, neuroscientists, artists, and psychologists—all in one place. Ultrahuman is available on iOS, Android, Mac, Apple Watch, Wear OS. Follow us on Twitter, Facebook, Instagram, and LinkedIn.Related FilesUltrahuman Mac App Press Release.pdf
Related Imagesultrahuman.png UltrahumanHolistic Fitness App
Quidel Corporation (NASDAQ: QDEL) ("Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has completed its investigation regarding a report of discordant results (False Positives) at a testing location in Vermont, and found no testing site- or product-related issues with the Sofia® 2 instrument or the Sofia® SARS Antigen FIA.
Quidel received a complaint in Vermont regarding false positive discrepant results among patients who were subsequently tested and found negative by PCR testing. Taking every complaint submission seriously, Quidel promptly entered the complaint into its Quality Management System and worked with the testing site to identify a potential root cause.
Quidel examined the complaint thoroughly, including an inspection of the testing site, analysis of the site’s data, and a review of approximately 110,000 data points generated at 526 sites in 33 other states currently using Quidel’s product. The investigation found that there were no issues with either the testing facility or with the quality of the Sofia products used. The results of the investigation determined that no further actions were necessary, and results were provided to the Vermont Department of Health, the Centers for Disease Control and Prevention, and the U.S. Food and Drug Administration.
"Quidel takes every complaint seriously and endeavors to identify the root cause of any complaint received,” said Douglas Bryant, president and CEO of Quidel Corporation. "We conducted a very thorough investigation for this unique complaint in Vermont and believe that it was highly likely that our Sofia® results were true positives and that the subsequent PCR method used to re-test was at risk of providing inaccurate results.”
Quidel currently sells the Sofia® SARS Antigen FIA in the United States under Emergency Use Authorization (EUA) by the FDA.
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage® and InflammaDry® leading brand names, as well as under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions, including, among others, COVID-19, influenza, respiratory syncytial virus, Strep A, lyme, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel's Triage® system of tests comprises a comprehensive test menu that provides rapid, cost-effective treatment decisions at the point-of-care (POC), offering a diverse immunoassay menu in a variety of tests to provide diagnostic answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians’ offices and hospital and reference laboratories. For more information about Quidel’s comprehensive product portfolio and to explore exciting employment opportunities, visit quidel.com.
This press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties. Many possible events or factors could affect our future financial results and performance, such that our actual results and performance may differ materially from those that may be described or implied in the forward-looking statements. As such, no forward-looking statement can be guaranteed. Differences in actual results and performance may arise as a result of a number of factors including, without limitation: the impact of the novel virus (COVID-19) global pandemic; an inability to agree on a definitive agreement or meet key deliverables and milestones under the NIH’s RADx-ATP contract; adverse changes in competitive conditions, the reimbursement system currently in place and future changes to that system, changes in economic conditions in our domestic and international markets, lower than anticipated market penetration of our products, our reliance on sales of our influenza and other respiratory or novel virus diagnostic tests, fluctuations in our operating results resulting from the timing of the onset, length and severity of cold and flu seasons, seasonality, government and media attention focused on influenza and other respiratory or novel viruses and the related potential impact on humans from such viruses, the quantity of our product in our distributors’ inventory or distribution channels, changes in the buying patterns of our distributors, and changes in the healthcare market and consolidation of our customer base; our development, acquisition and protection of proprietary technology rights; our development of new technologies, products and markets; our reliance on a limited number of key distributors; our exposure to claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us, including the ongoing litigation between us and Beckman Coulter, Inc.; intellectual property risks, including but not limited to, infringement litigation; our need for additional funds to finance our capital or operating needs; the financial soundness of our customers and suppliers; acceptance of our products among physicians and other healthcare providers; competition with other providers of diagnostic products; failures or delays in receipt of new product reviews or related to currently-marketed products by the U.S. Food and Drug Administration (the "FDA”) or other regulatory authorities or loss of any previously received regulatory approvals or clearances or other adverse actions by regulatory authorities; changes in government policies; costs of and adverse operational impact from failure to comply with government regulations in addition to FDA regulations; compliance with government regulations relating to the handling, storage and disposal of hazardous substances; third-party reimbursement policies and potential cost constraints; our failure to comply with laws and regulations relating to billing and payment for healthcare services; our ability to meet demand for our products; interruptions in our supply of raw materials; product defects; business risks not covered by insurance; costs and disruptions from failures in our information technology and storage systems; our exposure to data corruption, cyber-based attacks, security breaches and privacy violations; competition for and loss of management and key personnel; international risks, including but not limited to, compliance with product registration requirements, compliance with legal requirements, tariffs, exposure to currency exchange fluctuations and foreign currency exchange risk, longer payment cycles, lower selling prices and greater difficulty in collecting accounts receivable, reduced protection of intellectual property rights, social, political and economic instability, increased financial accounting and reporting burdens and complexities, taxes, and diversion of lower priced international products into U.S. markets; changes in tax rates and exposure to additional tax liabilities or assessments; risks relating to our acquisition and integration of the Triage MeterPro Cardiovascular and toxicology business and B-type Naturietic Peptide assay business (the "Triage and BNP Businesses”); that we may have to write off goodwill relating to our acquisitions; our ability to manage our growth strategy and identify and integrate acquired companies or technologies and our ability to obtain financing; the level of our indebtedness and deferred payment obligations; our ability to generate sufficient cash to meet our debt service and deferred and contingent payment obligations; that our Revolving Credit Facility is secured by substantially all of our assets; the agreements for our indebtedness place operating and financial restrictions on us and our ability to operate our business; that an event of default could trigger acceleration of our outstanding indebtedness; that we may incur additional indebtedness; increases in interest rate relating to our variable rate debt; dilution resulting from future sales of our equity; volatility in our stock price; provisions in our charter documents, Delaware law and the indenture governing our Convertible Senior Notes that might delay or impede stockholder actions with respect to business combinations or similar transactions; our intention of not paying dividends; and our ability to identify and successfully acquire and integrate potential acquisition targets. Forward-looking statements typically are identified by the use of terms such as "may,” "will,” "should,” "might,” "expect,” "anticipate,” "estimate,” "plan,” "intend,” "goal,” "project,” "strategy,” "future,” and similar words, although some forward-looking statements are expressed differently. The risks described in reports and registration statements that we file with the Securities and Exchange Commission (the "SEC”) from time to time, should be carefully considered. You are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date of this press release. Except as required by law, we undertake no obligation to publicly release the results of any revision or update of these forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200820005721/en/